> Antibody > Rabbit PAb Antibody > Anti-human SPARC / Osteonectin antibody (Antigen Affinity Purified) Anti-human SPARC / Osteonectin antibody (Antigen Affinity Purified)
| Catalog | Size (Price) | Quantity | In Stock | Operation | Other Information |
| 10929-RP02 |
|
YES |  |
    |
|
SPARC / BM-40 / Osteonectin Antibody ( Antigen Affinity Purified )
 |
Order or Inquire for SPARC Antibody product |  |
|
|
Detection limit is 0.5 ng/lane in WB |
SPARC / BM-40 / Osteonectin Antibody Product Information
| Immunogen : |
Recombinant human SPARC protein ( Catalog#10929-H08H ) |
| Antibody Type : | Rabbit Polyclonal Antibody ( Antibody Purification Platform ) |
| Ig Type : |
Rabbit IgG |
| Formulation : | 0.2 μm filtered solution in PBS with 5% trehalose |
| Preparation : |
Produced in rabbits immunized with purified, human cell-derived, recombinant human SPARC ( rh SPARC ; Catalog#10929-H08H ; NP_003109.1 ; Met 1- Ile 303 ). SPARC specific IgG was purified by human SPARC affinity chromatography. |
SPARC / BM-40 / Osteonectin Antibody Usage Guide
|
Specificity : |
Human SPARC / Osteonectin |
| Western blot : | This antibody can be used at 0.1 - 0.2 μg/mL with the appropriate secondary reagents to detect human SPARC in WB. Using a DAB detection system, the detection limit for human SPARC is approximately 0.5 ng/lane under non-reducing conditions and reducing conditions |
| Storage : | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free. Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles. |
SPARC / BM-40 / Osteonectin Antibody Related Products & Topics
Related Areas:
Stem Cell>>Mesenchymal Stem Cell (MSC)>>Osteoblast & Osteoclast Marker>>Osteonectin/SPARC
Stem Cell>>Embryonic Stem Cell (ESC)>>Embryonic Stem Cell Marker>>Osteonectin/SPARC
Cancer>>Angiogenesis>>ECM Molecules in Angiogenesis>>Osteonectin/SPARC
Immunology>>Adhesion Molecule>>Extracellular Matrix Molecule>>Extracellular Matrix Protein>>Osteonectin/SPARC
Proteins:
| Molecule | Species | Description //For Detailed Info.------CLICK! | Cat No | Size/Price |
| Osteonectin/SPARC | Human | Osteonectin/SPARC Protein, Recombinant | 10929-H08H | 100µg($290); Order |
Antibodies:
| Molecule | Application | Description //For Detailed Info.------CLICK! | Cat No | Size/Price |
| Human Osteonectin/SPARC |
WB, ELISA | Rabbit Polyclonal Antibody | 10929-RP01 | Order |
| Human Osteonectin/SPARC |
WB, ELISA | Rabbit Polyclonal Antibody (Antigen Affinity Purified) | 10929-RP02 | 100µg($250); Order |
SPARC / BM-40 / Osteonectin Antibody Background
Secreted protein acidic and rich in cysteine (SPARC), also known as Osteonectin (ON), is a member of the SPARC family. SPARC contains a EF-hand domain, a follistatin-like domain and a Kazal-like domain. It is expressed at high levels in tissues undergoing morphogenesis, remodeling and wound repair. SPARC has two calcium binding sites; an acidic domain that binds 5 to 8 Ca2+ with a low affinity and an EF-hand loop that binds a Ca2+ ion with a high affinity. SPARC appears to regulate cell growth through interactions with the extracellular matrix and cytokines.It binds calcium and copper, several types of collagen, albumin, thrombospondin, PDGF and cell membranes. The activity of SPARC is context- and cell-type-dependent, which is highlighted by the fact that SPARC has shown seemingly contradictory effects on tumor progression in both clinical correlative studies and in animal models. SPARC enhances the Wnt/beta-catenin signaling pathway and regulates the expression and posttranslational modification of collagen. SPARC might drive preadipocytes away from the status of growth arrest and therefore prevent terminal differentiation. SPARC could also decrease WAT deposition through its negative effects on angiogenesis.
References
- Sage, EH. et al.,2003, Curr Protoc Cell Biol .Chapter 10: Unit 10.11
- Fukunaga, KM. et al.,2007,Journal of investigative dermatology.127(11): 2497-8.
- Arnold, SA. et al.,2009, J Cell Commun Signal.
- Sussman, AN. et al.,2009, The American journal of pathology.174(5) :1827-36.